Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Francisco Ayala de la Peña"'
Autor:
Esmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Elisa García-Garre, Francisco Ayala de la Peña, Elena García-Martínez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundUp to 30% of breast cancer (BC) patients treated with neoadjuvant chemotherapy (NCT) will relapse. Our objective was to analyze the predictive capacity of several markers associated with immune response and cell proliferation combined with
Externí odkaz:
https://doaj.org/article/45fb4d2560e8406c9b0a23f5e2b11e43
Autor:
Esmeralda García-Torralba, Miguel Pérez Ramos, Alejandra Ivars Rubio, Esther Navarro-Manzano, Noel Blaya Boluda, Pilar de la Morena Barrio, Elisa García-Garre, Francisco Martínez Díaz, Asunción Chaves-Benito, Elena García-Martínez, Francisco Ayala de la Peña
Publikováno v:
Cancers, Vol 15, Iss 10, p 2846 (2023)
Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this study was to investigate the predictive and prognostic
Externí odkaz:
https://doaj.org/article/27dfeb1b4c474624ba02472b3566ba6c
Autor:
Alberto Carmona-Bayonas, Caterina Calderón, Raquel Hernández, Ana Fernández Montes, Beatriz Castelo, Laura Ciria-Suarez, Mónica Antoñanzas, Jacobo Rogado, Vilma Pacheco-Barcia, Elena Asensio Martínez, Alejandra Ivars, Francisco Ayala de la Peña, Paula Jimenez-Fonseca
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Quality of life (QoL) is a complex, ordinal endpoint with multiple conditioning factors. A predictive model of QoL after adjuvant chemotherapy can support decision making or the communication of information about the range of treatment optio
Externí odkaz:
https://doaj.org/article/8239bfeb60044c5d8981d76b9c9a0e1a
Autor:
Esther Navarro-Manzano, Ginés Luengo-Gil, Rocío González-Conejero, Elisa García-Garre, Elena García-Martínez, Esmeralda García-Torralba, Asunción Chaves-Benito, Vicente Vicente, Francisco Ayala de la Peña
Publikováno v:
Cancers, Vol 14, Iss 10, p 2390 (2022)
While the role of miR-200c in cancer progression has been established, its expression and prognostic role in breast cancer is not completely understood. The predictive role of miR-200c in response to chemotherapy has also been suggested by some studi
Externí odkaz:
https://doaj.org/article/04e787deaed74c8bb11c51b476395820
Autor:
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Publikováno v:
OncoImmunology, Vol 7, Iss 6 (2018)
Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to el
Externí odkaz:
https://doaj.org/article/6731cb15153b4509a97d8f6329ec4567
Autor:
Gines Luengo-Gil, Enrique Gonzalez-Billalabeitia, Sergio Alejo Perez-Henarejos, Esther Navarro Manzano, Asuncion Chaves-Benito, Elena Garcia-Martinez, Elisa Garcia-Garre, Vicente Vicente, Francisco Ayala de la Peña
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0194638 (2018)
BACKGROUND:Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recen
Externí odkaz:
https://doaj.org/article/dd106c7a60b943b68c3fd6b0448f99f6
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 35, Iss 1, Pp 12-14 (2013)
Externí odkaz:
https://doaj.org/article/ee8ec2ec2a7a43f8a4c49bbb6d38833c
Autor:
Francisco Ayala de la Peña, Keizo Kanasaki, Megumi Kanasaki, Sylvia Vong, Carlota Rovira, Raghu Kalluri
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e95888 (2014)
K-ras is essential for embryogenesis and its mutations are involved in human developmental syndromes and cancer. To determine the consequences of K-ras activation in urothelium, we used uroplakin-II (UPK II) promoter driven Cre recombinase mice and g
Externí odkaz:
https://doaj.org/article/84b53644cfb248058d3f98d866f22f9f
Autor:
Maria Carmen Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, David Zaragoza-Huesca, Carmen Ortega-Sabater, Jorge Peña-García, Salvador Espín, Guillermo Ricote, Sofía Montenegro, Francisco Ayala-De La Peña, Ginés Luengo-Gil, Andrés Nieto, Francisco García-Molina, Vicente Vicente, Francesco Bernardi, María Luisa Lozano, Victoriano Mulero, Horacio Pérez-Sánchez, Alberto Carmona-Bayonas, Irene Martínez-Martínez
Publikováno v:
Frontiers in Molecular Biosciences. 10
Introduction: Hepsin is a type II transmembrane serine protease and its expression has been linked to greater tumorigenicity and worse prognosis in different tumors. Recently, our group demonstrated that high hepsin levels from primary tumor were ass
Autor:
Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Marta Roche-Molina, María del Monte-Millán, Tatiana Massarrah, Yolanda Jerez, Francisco Ayala de la Peña, José Ángel García-Sáenz, Fernando Moreno, Álvaro Rodríguez-Lescure, Diego Malón-Giménez, Ana Isabel Ballesteros García, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Adrienne G. Waks, Sara M. Tolaney, Elizabeth A. Mittendorf, Ana Vivancos, Patricia Villagrasa, Joel. S. Parker, Charles M. Perou, Laia Paré, Guillermo Villacampa, Aleix Prat, Miguel Martín
Publikováno v:
JAMA Oncology.
ImportanceBiomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed.ObjectiveTo determine if use of the HER2DX genomic assay (Reveal Genomics) in pretr